Keystone Resort

Epic Passes Now On Sale for the 2024/25 Winter Season; Lock in the Lowest Price to Legendary Resorts Like Vail Mountain, Whistler Blackcomb, Park City Mountain, Breckenridge and More

Retrieved on: 
Tuesday, March 5, 2024
Cream, Condition, Investment, Telluride Ski Resort, Policy, Military, Epic, Veteran, Privacy, Canadian Armed Forces, Alpine, Pass, Woman, Australian Defence Force, Use, Perisher, Acquisition, Friends, Golf, Food, RFID, Mountain resort, Keystone Resort, Lethargy, Amusement park

With additional partner resorts like Telluride, the Epic Pass unlocks access to more than 80 resorts.

Key Points: 
  • With additional partner resorts like Telluride, the Epic Pass unlocks access to more than 80 resorts.
  • Offered ahead of the season, Epic Day Passes provide savings up to 65% compared to lift ticket prices.
  • Provides unlimited, unrestricted access to 42* resorts – including Vail Mountain, Beaver Creek Mountain Resort, Breckenridge Mountain, Keystone Resort, Park City Mountain, Whistler Blackcomb, as well as Andermatt-Sedrun-Disentis and Crans-Montana Mountain Resort* in Switzerland.
  • Epic Pass plans to provide access to Switzerland's Crans-Montana Mountain Resort: Vail Resorts plans to provide Pass Holders access to another international resort in the 2024/25 winter season.

Elicio Therapeutics Presents Preclinical Data on AMP-CpG Adjuvant in Combination with EBV Vaccine at the 2022 Keystone Symposia: Viral Immunity: Basic Mechanisms and Therapeutic Applications

Retrieved on: 
Wednesday, July 6, 2022
Cell, Massachusetts Institute of Technology, Epstein–Barr virus, AMP, FDA, Translational medicine, Koch Institute for Integrative Cancer Research, Patient, Adult, QIMR, Research, Keystone Resort, Engineering, GLOBE, Laboratory, COVID-19, Population, Immunization, Cancer, Multiple sclerosis, Biomedicine, Immunoglobulin G, H. Lee Moffitt Cancer Center & Research Institute, Compliance, Epithelium, QIMR Berghofer Medical Research Institute, Immune system, Infection, Lymph, Partnership, Degenerative disease, Immunotherapy, MIT, Hematological Cancer Research Investment and Education Act, Immunology, EBV, CD8, HLA, KRAS, Darrell Irvin, Koch Institute, Biomedical engineering, Vaccine, Amplifier, Vaccination, Epitope, Safety, Therapy, Forward-looking statement, ISCB Senior Scientist Award, Pharmaceutical industry, Amphiphile, Elicio Berriz

The data was presented at the 2022 Keystone Symposia on Viral Immunity Basic Mechanisms and Therapeutic Applications virtually and in-person at the Keystone Resort in Keystone, CO from June 29-July 2, 2022.

Key Points: 
  • The data was presented at the 2022 Keystone Symposia on Viral Immunity Basic Mechanisms and Therapeutic Applications virtually and in-person at the Keystone Resort in Keystone, CO from June 29-July 2, 2022.
  • EBV is a herpesvirus responsible for the well-known mononucleosis infections (mono) and has also been implicated in multiple lymphoid and epithelial cancers.
  • EBV targets both B cells and epithelial cells and utilizes their molecular machinery to replicate the viral genome.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.

Elicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications

Retrieved on: 
Wednesday, July 6, 2022
Mouse, Massachusetts Institute of Technology, AMP, FDA, Koch Institute for Integrative Cancer Research, Research and development, Keystone Resort, Chemokine, CpG, Engineering, Hematocrit, GLOBE, Pandemic, Infection, COVID-19, Thermoregulation, Immunization, Cancer, Laboratory, Omicron, TCR, Human, Immunoglobulin G, Cytokine, Development, Compliance, Immune system, Lymph, MIT, IND, Immunology, Animal, Viral, KRAS, RBD, Darrell Irvin, Koch Institute, Biomedical engineering, Vaccine, Primate, Amplifier, Vaccination, Immunotherapy, Severe acute respiratory syndrome coronavirus 2, Biomedicine, MD, Coronavirus, Therapy, Forward-looking statement, Doctor of Philosophy, Pharmaceutical industry, Amphiphile, Elicio Berriz, Research

ELI-005, containing the lymph node-targeted Amphiphile vaccine adjuvant AMP-CpG, induced potent, comprehensive and persistent innate immune responses in draining lymph nodes in mice.

Key Points: 
  • ELI-005, containing the lymph node-targeted Amphiphile vaccine adjuvant AMP-CpG, induced potent, comprehensive and persistent innate immune responses in draining lymph nodes in mice.
  • The robust immune responses generated by ELI-005 suggest that it may enhance broad protection against new variants of concern.
  • We are pleased to present updated data from ongoing preclinical work in mice and non-human primates with ELI-005, our lymph node-targeting AMP-vaccine against SARS-CoV-2.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.

Vail Resorts Announces Enhancements to the Guest Experience For 2021-22 Winter Season

Retrieved on: 
Tuesday, November 16, 2021
Okemo Mountain, Efficiency, Safety, McCoy Park, Perisher, GPS, Crested Butte Mountain Resort, Technology, Skiing, New, Multimedia, MTN, SRS, Brandywine, Snow, Sale, Travel, Kirkwood Mountain Resort, Food, Data science, NYSE, Collection, Paoli Peaks, Keystone Resort, Pass, Breckenridge Ski Resort, Weather, Animal, Amusement park, Oil, Tourism

BROOMFIELD, Colo., Nov. 16, 2021 /PRNewswire/ -- As Vail Resorts begins to welcome skiers and riders back for a highly anticipated winter, the company is announcing new strategies taking effect during the 2021-22 North American season to enhance the guest experience and prioritize its pass holders.

Key Points: 
  • Guests planning to visit the resorts during those dates are strongly encouraged to purchase their lift access in advance.
  • Vail Resorts has spent more than a decade investing in technology, data science and analytics to improve the guest experience.
  • For the upcoming 2021-22 North American ski and ride season, the company is unveiling several new on-mountain projects across five resorts to enhance the guest experience.
  • Vail Resorts Development Company is the real estate planning and development subsidiary of Vail Resorts, Inc. Vail Resorts is a publicly held company traded on the New York Stock Exchange (NYSE: MTN).